Santariškių g. 2, 08661 Vilnius
tel. (+370) 5 236 5000
faks. (+370) 5 236 5111
info@santa.lt

      

SANTAROS KLINIKOS

VILNIAUS UNIVERSITETO LIGONINĖ

Научная деятельность

Spausdinti

ЦГОТ считает приоритетным направление развития биомедицинских исследований, благодаря которым в медицине появляются инновации, а пациенты имеют возможность получить лечение, основанное на применении новейших технологий. ЦГОТ организует и развивает эпидемиологические, диагностические исследования. 

ЦГОТ сотрудничество с международными организациями;

Oрганизация
Год вступления
ЦГОТ статус
Ссылка
Название
NMSG
www. nordic-myeloma.org
Nordic Myeloma Study Group 2015
Член/ Научно-исследовательский центр
Hemato Oncology Foundation for Adults in Netherlands 2014
Научно-исследовательский центр
European Organisation for Research and Treatment of Cancer 2012
Член/ Научно-исследовательский центр
2ewww.nopho.org
Nordic Society of Pediatric Haematology and Oncology
2010
Научно-исследовательский центр
3e
www.leukemia-net.org
European Leukemia Net
2010
Член
4e
www.ebmt.org
European Group for Blood and Marrow Transplantation
2003
Член

По инициативе ЦГОТ создана Система гематологического мониторинга (СГЕМ). Это информационная система, при помощи которой накапливаются данные о новых случаях обнаружения рака. Эта система позволяет также следить за ходом лечения болезни и эффективностью. Собранные при помощи СГЕМ данные анализируются, а на основе полученных результатов делаются выводы об эпидемиологии рака крови, а также об эффективности назначаемого лечения, тенденциях.

Врачи, работающие в Центре, постоянно принимают участие в международных конференциях, где узнают о новинках современной мировой медицины, представляют диагностические возможности ЦГОК, а также результаты лечения. Центр принимает активное участие и в деятельности Литовского гематологического общества, организует конференции, на которые приглашаются специалисты из Литвы и из-за рубежа.

Биомедицинские исследования ЦГОТ

Объект исследования

Название исследования

Характер исследования

Дата одобрения Комитетом по биоэтике, Nr./ EudraCT Nr.

Заказчик

Гематология

ОМЛ и миелодиспластический синдром (МДС)  высокого риска

Многоцентровое исследование случайного отбора II фазы с целью оценки переносимости и эффективности назначения ибрутиниба с 10-дневным лечением децитабином пациентов в возрасте ≥ 66 лет, с индексом КОМОРБИДНОСТИ (HCT-CI ≥ 3 ), которые страдают острым миелоидным лейкозом (ОМЛ) и миелодиспластическим синдромом (МДС)  высокого риска (IPSS-R > 4,5)

Интервенционный

2017-05-22,

Nr. PP-114

EudraCT Nr.:

2015-002855-85

 

HOVON

Острый лейкоз высокого риска

Рандомизированное исследование III фазы гаплоидентичной HCT (трансплантация кроветворных клеток) со стратегией возврата  донорских лимфоцитов HSV-TК или без нее, у пациентов, страдающих острым лейкозом высокого риска

Интервенционный

2016-12-22,

Nr. P-16-72

EudraCT Nr.:

2009-012973-37

MolMed S.p.A.

Рецидивирующая или рефрактерная Т-клеточная лимфобластная лейкемия или Т-клеточная лимфобластная лимфома

Исследование фазы II против CD38 направленного моноклонального антитела, по безопасности и эффективности изатуксимаба, путем внутривенной(IV)  инфузии, у пациентов с рецидивирующей или рефрактерной Т-клеточной лимфобластной лейкемией или Т-клеточной лимфобластной лимфомой

Интервенционный

2016-10-24,

Nr. P-16-62

EudraCT Nr.:

2016-002739-14

 

Sanofi-aventis

Множественная миелома

Клиническое исследование II фазы – индукционное лечение карфилзомибом, циклофосфамидом и дексаметазоном, а также химиотерапией высоких доз с трансплантацией стволовых кроветворных клеток, после которой применяется рандомизации между поддерживающим лечением карфилзомибом -дексаметазоном или наблюдением за пациентами, у которых возобновилась множественная миелома после предварительной химиотерапии высоких доз с трансплантацией стволовых кроветворных клеток.

Интервенционный

2016-03-21,

Nr. P-16-15

EudraCT Nr.:

2013‐003789-15

Nordic Myeloma Study Group

Трансплантат против хозяина

Исследование медицинского ухода и клинического течения болезни Трансплантат против хозяина. Nr.: TPSL-LTU-2015.

Ретроспективный -  проспективный, наблюдение

2015-11-03; Nr. 158200-15-814-326

Ассоциация исследователей гематологии и онкологии LTU

Хронический лимфолейкоз

Многоцентровое, открытое исследование случайного отбора III фазы с тремя группами, предназначенное для исследования сочетания обинутузумаба и хлорамбуцила, сочетания ACP-196 и обинутузумаба, а также монотерапии ACP-196 для пациентов, страдающих хроническим лимфолейкозом и раннее не получавшим лечения от него.

Интервенционный

2015-06-25, Nr. P-15-43/1

EudraCT Nr.: 2014-005582-73

Acerta Pharma B. V.

Пароксизмальная ночная гемоглобинурия (ПНГ)

 

Открытое исследование, проверяющее концепцию, предназначенное для оценки эффективности, безопасности и фармакокинетики LFG316 против С5 моноклонального антитела, назначая его пациентам с пароксизмальной ночной гемоглобинурией (ПНГ).

Интервенционный

2015-06-25, Nr. P15-39

 

EudraCT Nr.: 2014-005338-74

 

Novartis Pharma Services AG

Острый миелоидный лейкоз

EORTC-1301-LG: 10-дневное лечение децитабином в сравнении с обычной химиотерапией („3+7“), позже выполняя пациентам, ≥ 60 лет, страдающим ОМЛ, аллогенную трансплантацию: исследование III фазы случайной выборки EORTC группы лейкемии, CELG, GIMEMA и немецкой MDS группы.

 

Интервенционный

2014-12-19,
Nr. P-14-69

EudraCT Nr.: 2014-001486-27

EORTC

Острый миелоидный лейкоз

Рандомизированное исследование пациентов 18-65 лет, страдающих не подвергавшимся лечению миелоидным лейкозом (ОМЛ) или миелодиспластическим синдромом (МДС) высокого риска (IPSS-R значение риска > 4,5), добавочного значения лечения леналидомидом, с вводной фазой определения дозы, комбинируя его со стандартной индукционной химиотерапией ремиссии и лечением после ремиссии.

Интервенционный

2014-07-23, Nr. P-14-42

EudraCT Nr.: 2013-002843-26

HOVON

Тромбическая микроангиопатия

Неконтролируемое, двухуровневое когортное исследование II фазы, предназначенное для оценки безопасности, фармакокинетики, фармакодинамики, иммуногенности и клинической эффективности OMS721 у взрослых пациентов с тромбическими микроангиопатиями.

Интервенционный

2014-07-17, Nr. P-14-36/2

EudraCT Nr.: 2014-001032-11

Omeros Corporation

Хронический лимфолейкоз

Многоцентровое, открытое международное исследование одной ветви III В фазы для оценки безопасности обинутузумаба, употребляемого в одиночку или вместе с химиотерапией для испытуемых, страдающих ранее не подвергавшимся лечениюрецидивировавшим или устойчивым хроническим лимфолейкозом.

Интервенционный

2014-05-21, Nr. PP-102

EudraCT Nr.: 2013-000087-29

UAB „Roche“ Lietuva

Гемофилия A

 

Непрерывное исследование 3b фазы о безопасности и эффективности пегилированного  Rodomas vertimas Пароксизмальная ночная гемоглобинурия (ПНГ) Atviras koncepcijos patvirtinimo tyrimai prieš C5 veikiančio monokloninio antikūno LFG316 veiksmingumui, saugumui ir farmakokinetikai įvertinti, skiriant pacientams, kuriems yra paroksizminė naktinė hemoglobinurija (PNH).

Išversti vietoje Пароксизмальная ночная гемоглобинурия (ПНГ) Atviras koncepcijos patvirtinimo tyrimas prieš C5 veikiančio monokloninio antikūno LFG316 veiksmingumui, saugumui ir farmakokinetikai įvertinti, skiriant pacientams, kuriems yra paroksizminė naktinė hemoglobinurija (PNH).

рекомбинантного фактора VIII (rFVIII-PEG; BAX 855), назначая его для профилактики кровотечений ранее подвергавшимся лечению пациентам, страдающим тяжелой формой гемофилии А.

Интервенционный

2013-10-21, Nr.P-13-77/1

EudraCT Nr.: 2013-001359-11

Baxter Innovations GmbH

Множественная миелома

Многоцентровое двойное слепое исследование случайной выборки, предназначенное для сравнения деносумаба и золедроновой кислоты (Zometa®) для лечения больных с впервые диагностированной множественной миеломой.

Интервенционный

2013-09-06, Nr. P-13-65/2

EudraCT Nr.: 2010-020454-34

Amgen Aktiebolag

Множественная миелома

Исследование клона злокачественных плазматических клеток костного мозга адгезивного иммунофенотипа исвязи генетических аберраций с циркулирующими плазматическими клетками. Nr.: PLAG-LTU-2012

Проспективный, не интервенционный

2013-02-12, Nr. 158200-13-587-177

 

Ассоциация исследователей гематологии и онкологии LTU

Первичный миелофиброз

Популяционный клинический и генетический анализ пациентов Литвы, страдающих первичным миелофиброзом. Nr:. PMF-LTU-01

Наблюдение

2012-11-29, Nr. 158200-12-545-156

Ассоциация исследователей гематологии и онкологии LTU

Острый лимфобластный лейкоз

Протокол NOPHO-ALL 2008 для лечения острой лимфобластной лейкемии у молодых взрослых пациентов (возраст 18-45 лет)

Интервенционный

2011-05-24, Nr. P-11-43

EudraCT Nr.: 2011-000908-18

Nordic Society of Paediatric Haematology and Oncology

Онкология

Метастатическая саркомамягких тканей

Многоцентровое исследование II фазы, сравнивающее эффективность орального ингибитора ангиогенеза нинтетанибаи внутривенного цитотоксического препарата ифосфамида для лечения пациентов с распространенной метастатической саркомой мягких тканей, возобновившейся после системной химиотерапии первой линии, предназначенной для неоперабельного заболевания, на основе неоксазафоспорина («ANITA»)

Interventional

2017-08-29,

Nr. P-17-42

EudraCT Nr.:

2016-002093-12

EORTC

Проведение инвестиционными биомедицинских исследований тесно связано с национальными и международными проектами, осуществляемыми в центре. Проекты ЦГОТ:

Источник финансирования Проект Состояние
Финансовые механизмы экономического пространства Европы и Норвегии LT0040 «Академические клинические исследования онкогематологических биомаркеров и индивидуального лечения» Осуществлен
LT0112 «Национальная программа исследований наследственного рака у детей» Осуществлен
Научный совет Литвы LIG-19/2010 «Молекулярные маркеры предупреждения рака груди и яичников, ранней диагностики и лечения». Осуществлен
«Целенаправленное новое секвенирование для выявления генетической предиспозиции к раку груди, яичников и толстой кишки». В процессе осуществления

 Публикации:

  1. Winston D.J., ... , Trociukas I., et al., Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial. The Lancet, May - Jun (2018). Резюме публикации
  2. McLornan D.P., ... , Griskevicius L., et al., Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT. British Journal of Haematology, May (2018). Резюме публикации
  3. Valatkaite-Rakstiene B, Cekauskiene R, Griskevicius L, Jakubauskas A.  Two novel HLA-C alleles, HLA-C*02:02:34 and HLA-C*03:369, were identified in the same individual. International Journal of Immunogenetics, May (2018). Резюме публикации
  4. Vaisvilas M., Buseckaite S., Mickeviciute O., Cekauskiene R., Griskevicius L., Peceliunas V.  High-dose methylprednisolone for the treatment of sinusoidal obstruction syndrome in adults. Bone Marrow Transplantation, Jan 29 (2018). Резюме публикации
  5. Bukauskas A., Griskevicius L., Peceliunas V. Lessons Learned from early experiences with vedolizumab for steroid-refractory acute graft- versus-host disease with gastrointestinal involvement. Biol Blood Marrow Transplant, Sep (2017). Резюме публикации
  6. Giles F.J., ... , Griskevicius L., et. al., Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis. J Cancer Res Clin Oncol. Aug (2017)  Резюме публикации
  7. Beisa A., ..., Griskevicius L., et. al., The utility of the Bethesda category and its association with BRAF mutation in the prediction of papillary thyroid cancer stage. Langenbecks Arch Surg, Mar (2017)  Резюме публикации
  8. Toft N., ... , Griskevicius L.,  et al., Results of NOPHO ALL2008 treatment for patients 1-45 years with acute lymphoblastic leukemia. Leukemia, Aug 18 (2017). Резюме публикации
  9. Dirse V., Norvilas R., Gineikiene E., Matuzevičienė R., Griskevicius L., Preiksaitiene E., ETV6 and NOTCH1 germline variants in adult acute leukemia. Leukemia & Lymphoma,  Aug 4 (2017). Резюме публикации
  10. Stegmayr B, ... , Griskevicius A., Audzijoniene J., et al., Distribution of indications and procedures within the framework of centers participating in the WAA apheresis registry. Transfusion and Apheresis Science, Feb, 56(1):71-74 (2017). Резюме публикации
  11. Valatkaite-Rakstiene B. ,  Cekauskiene R., Griskevicius L., Jakubauskas  A., Identification of a novel HLA-B*13 allele, HLA-B*13:99, by sequence-based typing in German bone marrow donor. HLA, Feb 5 (2017). Pезюме публикации
  12. Beisa A., Kvietkauskas M., Beisa V., Stoskus M., Ostaneviciute E., Jasiunas E., Griskevicius L., Strupas K., The utility of the Bethesda category and its association with BRAF mutation in the prediction of papillary thyroid cancer stage. Langenbecks Arch Surg, Feb 03 (2017). Pезюме публикации
  13. Hoffmann V.S., ... , Griskevicius L., et al., Treatment and outcome of 2904 CML patients from the EUTOS population-based registry. Leukemia, Aug 29 ( 2016). Pезюме публикации
  14. Jewell R.C, Kipps T.J., Dürig J., Griskevicius L., Stilgenbauer S., Smolej L., Mayer J., Hess G., Hernandez-Ilizaliturri F.J., Padmanabhan-Iyer S., Fang L., Goldstein N., Gorczyca M., Gupta I., Lisby S., Wierda W.G.; Hx-CD20-407 Study Investigators. Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy. Leukemia & Lymphoma, Jul 7:1-9 (2016). Резюме публикации
  15. Brand B., Gruppo R., Wynn T.T., Griskevicius L., Lopez Fernandez M.F., Chapman M., Dvorak T., Pavlova B.G., Abbuehl B.E. Efficacy and safety of pegylated full-length recombinant factor VIII with extended half-life for perioperative haemostasis in haemophilia A patients. Haemophilia, Jul 22(4):e251-8 (2016). Резюме публикации
  16. Rimsevicius L., Bagarauskyte R., Griskevicius A., Audzijoniene J., Griskevicius L., Miglinas M. Successful adsorption of anti-A/B antibodies with multiple personal use columns in AB0 incompatible kidney recipients: A single centre experience. Journal of Clinical Apheresis, Jun 22 (2016). Резюме публикации
  17. Stoskus M, Eidukaite A, Griskevicius L. Defining the significance of IGF2BP1 overexpression in t(12;21)(p13;q22)-positive leukemia REH cells. Leukemia Research, Aug, 47:16-21 (2016). Резюме публикации
  18. Dirse V., Gineikiene E., Zvirblis T., Bertasiute R., Paulssonc K., Griskevicius L. Single nucleotide polymorphism array analysis of clonal evolution in younger adult acute lymphoblastic leukemia. Leukemia & Lymphoma, Mar 21:1-4 (2016). Резюме публикации
  19. Beinortas T., Tavoriene I., Zvirblis T., Gerbutavicius R., Jurgutis M., Griskevicius L. Chronic myeloid leukemia icidence, survival and accesibility of tyrosine kinase inhibitors: a report from population-based Lithuanian haematological disease registry 2000-2013. BMC Cancer, 16(1):198 (2016). Резюме публикации
  20. Beiša A, Beiša V, Stoškus M, Ostanevičiūtė E, Griškevičius L, Strupas K., The value of the repeated examination of BRAF V600E mutation status in diagnostics of papillary thyroid cancer. Endokrynologia Polska, 67 (1): 35–40. (2016). Резюме публикации
  21. Stoskus M, Vaitkeviciene G, Eidukaite A, Griskevicius L., ETV6/RUNX1 transcript is a target of RNA-binding protein IGF2BP1 in t(12;21)(p13;q22)-positive acute lymphoblastic leukemia. Blood Cells , Molecules and Diseases, 57:30-34. (2016). Резюме публикации
  22. Mörtzell Henriksson M, ...., Griskevicius A. et al. Adverse events in apheresis: An update of the WAA registry data. Transfusion and Apheresis Science. (2016). Резюме публикации
  23. Hochhaus A, ... , Griskevicius L. et al. Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study. Leukemia. Jan; 30(1):57-64. (2016). Резюме публикации
  24. Dirse V., Bertasiute A, Gineikiene E, Zvirblis T, Dambrauskiene R, Gerbutavicius R, Juozaityte E, Malciute L, Paulsson K, Griskevicius L. : A population-based single nucleotide polymorphism array analysis of genomic aberrations in younger adult acute lymphoblastic leukemia patients. Genes Chromosomes Cancer. May; 54(5):326-33. (2015). Резюме публикации.
  25. Blanco I, ... , Janavicius R et al., Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers. PLoS One. Apr 1; 10(4):e0120020 (2015). Резюме публикации.
  26. Peterlongo P, , ... , Janavicius R et al., Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. Jan; 24(1):308-16 (2015). Резюме публикации.
  27. Giedraitienė N., ..., Griškevičius L. et al. Therapeutic Plasma Exchange in Multiple Sclerosis Patients with Abolished Interferon-beta Bioavailability. Med Sci Monit. 21:1512-9 (2015). Резюме публикации.
  28. Maliukevičiūtė, I., ..., Griškevičius, A. et al. AB0 nesuderinamumas neturi įtakos ankstyvam inkstų transplanto funkcionavimui po gyvų donorų organų transplantacijos. Medicinos teorija ir praktika, 21:231-234 (2015).
  29. Toft, N., ..., Griskevicius, L. et al. Toxicity profile and treatment delays in NOPHO ALL2008 - comparing adults and children with Philadelphia chromosome-negative acute lymphoblastic leukemia. Eur J Haematol, (2015). Резюме публикации.
  30. Rebbeck, T.R., ..., Janavicius, R. et al. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA, 313:1347-61 (2015). Резюме публикации.
  31. Hoffman, V.S., ..., Griskevicius, L. et al. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries. Leukemia, 29:1336–1343 (2015). Резюме публикации.
  32. Kuchenbaecker, K.B., ..., Janavicius, R. et al. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 47:164-171 (2015). Резюме публикации.
  33. White, H., ..., Gineikiene, E. et al. A certified plasmid reference material for the standardisation of BCR–ABL1 mRNA quantification by real-time quantitative PCR. Leukemia, 29:369-376 (2015). Резюме публикации.
  34. Buser L., Bihl M., Rufle A., Mickys U., Tavoriene I., Griskevicius L., Tzankov A. Unique Composite Hematolymphoid Tumor Consisting of a Pro-T Lymphoblastic Lymphoma and an Indeterminate Dendritic Cell Tumor: Evidence for Divergent Common Progenitor Cell Differentiation. Pathobiology, 81:199-205 (2014). Резюме публикации.
  35. Janavičius R, Rudaitis V, Mickys U, Elsakov P, Griškevičius L., Comprehensive BRCA1 and BRCA2 mutational profile in Lithuania. Cancer Genet. May; 207(5):195-205 (2014). Резюме публикации.
  36. Osorio A , ... , Janavicius R et al. DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. PLoS Genet. Apr 3; 10(4):e1004256 (2014). Резюме публикации.
  37. Dymerska D , ... , Janavicius R et al. Lynch syndrome mutations shared by the Baltic States and Poland. Clin Genet. Aug; 86(2):190-3 (2014).
  38. Dirse V., Burnyte B., Gineikiene E., Griskevicius L. and Utkus A. 2014 A novel de novo 2.5 Mb microdeletion of 7q22.1 harbours candidate gene for neurobehavioural disorders and mental retardation. Journal of Genetics, 93 (2014).
  39. J. Rascon, L. Rageliene, S. Stankeviciene, D. Palionis, A.E. Tamosiunas, N. Valeviciene, T. Zvirblis, An assessment of iron overload in children treated for cancer and nonmalignant hematologic disorders. Eur J Pediatr (2014). Резюме публикации.
  40. Rudaitis V, Zvirblis T, Kanopiene D, Janulynaite D, Griskevicius L, Janavicius R. BRCA1/2 mutation status is an independent factor of improved survival for advanced (stage III-IV) ovarian cancer. Int J Gynecol Cancer, 24(8):1395-400 (2014). Резюме публикации.
  41. Samalavicius R., Serpytis M., Ringaitiene D., Grazulyte D., Bertasiute R., Rimkus B., Matulionyte R., Ambrazaitiene R., Sipylaite J., Kacergius T., Griskevicius L. Successful use of extracorporeal membrane oxygenation in a human immunodeficiency virus infected patient with severe acute respiratory distress sindrome. AIDS Research and Therapy, 11(37):1-6 (2014). Резюме публикации.
  42. G. Vaitkevičienė, R. Matuzevičienė, M. Stoškus, T. Zvirblis, L. Ragelienė, K. Schmiegelow, Cure rates of childhood acute lymphoblastic leukemia in Lithuania and the benefit of joining international treatment protocol. Medicina, 50(1):28-36 (2014) . Резюме публикации.
  43. Frandsen TL, Heyman M, Abrahamsson J, Vettenranta K, Asberg A, Vaitkeviciene G, Pruunsild K, Toft N, Birgens H, Hallbook H, Quist-Paulsen P, Griskevicius L, Helt L, Vilsbol Hansen B, Schmiegelow Kjeld, Complying with the European Clinical Trials directive while surviving the administrative pressure – An alternative approach to toxicity registration in a cancer trial. European Journal of Cancer, 50:251-259 (2014). Резюме публикации.
  44. Guitard J, Degulys A, Buot G, Aline-Fardin A, Dannaoui E, Rio B, Marie JP, Lapusan S, Hennequin C, Acremonium sclerotigenum-Acremonium egyptiacum: a multi-resistant fungal pathogen complicating the course of aplastic anaemia. Clinical Microbiology and Infection, 20(1):O30-O32 (2014). Резюме публикации.
  45. Jakubauskas A, Valatkaite B, Griskevicius L, Identification of a novel HLA-B allele, B*56:43, by sequence-based typing in Lithuania bone marrow donor. Tissue Antigens, 83: 52-64 (2014).
  46. Stegmayr B, Ptak J, Nillson T, Berlin G, Mirea V, Axelsson C G, Griskevicius A, Centoni P, Liumbruno G, Audzijoniene J, Mokvist K, Lassen E, Knutson F, Norda R, Mortzell M, Prophet H, Ramlow W, Blaha M, Witt V, Efvergren M, Tomaz J, Newman E, Eloot S, Dhondt A, Lalic K, Sikole A, Derfler K, Hrdlickova R, Tomsova H, Gasova Z, Bhuiyan-Ludvikova Z, Ramsauer B, Vrielink H, Panorama of adverse events during cytapheresis. Transfusion and apheresis science, 48: 155-156 (2013).
  47. Couch FJ, , Janavicius R et al. Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet.; 9(3):e1003212. (2013). Резюме публикации.
  48. Griskevicius A, Audzijoniene J, Griskevicius L, Petrulioniene Z, Laucevicius A, The lipoproteins selections aphereses with LDL Lipopak 400. Transfusion and Apheresis Science, 48: 183 (2013).
  49. Jakubauskas A, Valatkaite B, Griskevicius L, Two novel HLA class II alleles, DRB1*11:31 and DQB1*05:01:05, identified by sequence-based typing. Tissue antigens, 82: 293-300 (2013).
  50. Vaitkeviciene G, Heyman M, Jonsson OG, Lausen B, Harila-Saari A, Stenmarker M, Taskinen M, Zvirblis T, Asberg A, Groth-Pedersen L, Rageliene L, Schmiegelow K, Early morbidity and mortality in childhood acute lymphoblastic leukemija with very high white blood cell count. Leukemia, 1-4 (2013).
  51. Janavicius R, Rudaitis V, Feng B J, Ozolina S, Griskevicius L, Galdgar D, Tihomirova L, Haplotype analysis and ancient origin of the BRCA1 c.41035delA Baltic founder mutation. European Journal of Medical Genetics, 56(3): 125-130 (2013). Резюме публикации. 
  52. Toft N, Birgens H, Abrahamsson J, Bernell P, Griskevicius L, Hallböök H, Heyman M, Holm MS, Hulegårdh E, Klausen TW, Marquart HV, Jónsson OG, Nielsen OJ, Quist-Paulsen P, Taskinen M, Vaitkeviciene G, Vettenranta K, Asberg A, Schmiegelow K,Risk group assignment differs for children and adults 1-45 yr with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol. European Journal of Haematology, 90(5): 404-412 (2013). Резюме публикации.
  53. Gineikiene E, Seinin D, Brasiuniene B, Brazaitis A, Griskevicius L, Jakubauskas A, Clear cell sarcoma expressing a novel chimerical transcript EWSR1 exon 7/ATF1 exon 6. Virchows Archiv, 461(3): 339-343 (2012). Резюме публикации.
  54. Cortes JE, Kim DW, Kantarjian HM, Brümmendorf TH, Dyagil I, Griskevicius L, Malhotra H, Powell C, Gogat K, Countouriotis AM, Gambacorti-Passerini C, Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial, J Clin Oncol (2012). Резюме публикации.
  55. A.L. Petzer, D. Fong, T. Lion, I. Dyagil, Z. Masliak, A. Bogdanovic, L. Griskevicius, S. Lejniece, S. Goranov, L. Gercheva, A. Stojanovic, D. Peytchev, N. Tzvetkov, R. Griniute, A. Stanchev, T. Grubinger, M. Kwakkelstein, P. Schuld, G. Gastl, D. Wolf, High dose imatinib induction followed by standard dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients - final analysis of a randomised multicentre phase III trial. Haematologica, 97: 1562-1569 (2012). Резюме публикации.
  56. Couch FJ, ..., Janavicius R et al., Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev., 21(4):645-57 2012. Резюме публикации.
  57. Ramus SJ, ..., Janaviciu R et al., Chenevix-Trench G; Consortium of Investigators of Modifiers of BRCA1/2. Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Hum Mutat., 33(4):690-702 (2012). Резюме публикации.
  58. V. Peceliunas, A. Janiulioniene, R. Matuzeviciene, T. Zvirblis, L. Griskevicius, Circulating plasma cells predict the outcome of relapsed or refractory multiple myeloma. Leuk. Lymphoma, 53:641–647 (2012). Резюме публикации.
  59. Ding YC,..., Janavicius R et al. A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. Aug; 21(8):1362-70 (2012). Резюме публикации.
  60. Janavicius R, Elsakov P. Novel germline MSH2 mutation in lynch syndrome patient surviving multiple cancers. Hered Cancer Clin Pract., 10(1):1 (2012). Резюме публикации.
  61. Mavaddat N, ..., Janaviciu R et al., Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev., 21(1):134-47 (2012). Резюме публикации.
  62. Antoniou AC, ..., Janavicius R et al., Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet. 15, 20(16):3304-21 (2011). Резюме публикации.
  63. Martrat G,..., Janavicius R et al. Exploring the link between MORF4L1 and risk of breast cancer. Breast Cancer Res. Apr 5; 13(2):R40. (2011). Резюме публикации.
  64. Ramus SJ,..., Janavicius R et al. Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. Jan 19; 103(2):105-16. (2011). Резюме публикации.
  65. Mulligan AM, ..., Janavicius R et al., Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res., 13(6):R110 (2011). Резюме публикации.
  66. W.G. Wierda, T.J. Kipps, J. Durig, L. Griskevicius, S. Stilgenbauer, J. Mayer, L. Smolej, G. Hess, R. Griniute, F.J. Hernandez-Ilizaliturri, S. Padmanabhan, M. Gorczyca, C.N. Chang, G. Chan, I. Gupta, T.G. Nielsen, C.A. Russell, Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood, 117:6450–6458 (2011). Резюме публикации.
  67. M. Stoskus, E. Gineikiene, V. Valceckiene, B. Valatkaite, R. Pileckyte, L. Griskevicius, Identification of characteristic IGF2BP expression patterns in distinct B-ALL entities. Blood Cells Mol. Dis., 46:321–326 (2011). Резюме публикации.
  68. R. Pileckyte, M. Jurgutis, V. Valceckiene, M. Stoskus, E. Gineikiene, J. Sejoniene, A. Degulys, T. Zvirblis, L. Griskevicius, Dose-dense high-dose methylprednisolone and rituximab in the treatment of relapsed or refractory high-risk chronic lymphocytic leukemia. Leuk. Lymphoma, 52:1055–1065 (2011). Резюме публикации.
  69. V. Peceliunas, A. Janiulioniene, R. Matuzeviciene, L. Griskevicius, Six color flow cytometry detects plasma cells expressing aberrant immunophenotype in bone marrow of healthy donors. Cytometry B Clin. Cytom., 80B(5):318–323 (2011). Резюме публикации.
  70. V. Peceliunas, A. Janiulioniene, R. Matuzeviciene, L. Griskevicius, Flow cytometric detection of immunophenotypically normal plasma cells in multiple myeloma patients provides clinically important information. Laboratorinė medicina, 13(2):59-64 (2011).
  71. R. Janavicius, K. Andrekute, U. Mickys, V. Rudaitis, B. Brasiuniene, L. Griskevicius, Apparently "BRCA-related" breast and ovarian cancer patient with germline TP53 mutation. Breast J., 17:409–415 (2011). Резюме публикации.
  72. Jakubauskas, R. Vilkeviciene, D. Juskevicius, L. Griskevicius, Identification of a novel HLA-B allele, B*56:31, by sequence-based typing in a Lithuanian individual. Tissue Antigens, 77:262–263 (2011). Резюме публикации.
  73. Jakubauskas, V. Valceckiene, K. Andrekute, D. Seinin, A. Kanopka, L. Griskevicius, Discovery of two novel EWSR1/ATF1 transcripts in four chimerical transcripts-expressing clear cell sarcoma and their quantitative evaluation. Exp. Mol. Pathol., 90:194–200 (2011). Резюме публикации.
  74. Jakubauskas, D. Juskevicius, L. Griskevicius, C*07:185, a novel HLA-C*07 allele identified by sequence-based typing. Tissue Antigens, 78:155–156 (2011).
  75. Jakubauskas, L. Griskevicius, Sequence-based typing showed a novel HLA-DQB1*05 allele, DQB1*05:01:03. Tissue Antigens, 77:157–158 (2011).
  76. V. Valceckiene, R. Kontenyte, A. Jakubauskas, L. Griskevicius, Selection of reference genes for quantitative polymerase chain reaction studies in purified B cells from B cell chronic lymphocytic leukaemia patients. Br. J. Haematol., 151:232–238 (2010). Резюме публикации.
  77. A.L. Petzer, D. Wolf, D. Fong, T. Lion, I. Dyagil, Z. Masliak, A. Bogdanovic, L. Griskevicius, S. Lejniece, S. Goranov, L. Gercheva, A. Stojanovic, D. Peytchev, N. Tzvetkov, R. Griniute, R. Oucheva, H. Ulmer, M. Kwakkelstein, F. Rancati, G. Gastl, High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study. Haematologica, 95:908–913 (2010). Резюме публикации.
  78. M. Janeliūnienė, R. Matuzevičienė, L. Griškevičius, Z.A. Kučinskienė. Monitoring of T-cell Acute Lymphoblastic Leukemia by Flow Cytometry. Central Europeen Journal of Medicine, 5(6):651-658 (2010).
  79. Janavičius R. Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control. EPMA Journal. Sep; 1(3):397-412 (2010). Резюме публикации.
  80. R. Janavicius, D. Matiukaite, A. Jakubauskas, L. Griskevicius, Microsatellite instability detection by high-resolution melting analysis. Clin. Chem., 56:1750–1757 (2010). Резюме публикации.
  81. Jakubauskas, L. Griskevicius, Haplotype-specific sequencing reveals a novel HLA-A*03 allele, A*030114. Tissue Antigens, 76:71–75 (2010).
  82. Jakubauskas, L. Griskevicius, KRas and BRaf mutational status analysis from formalin-fixed, paraffin-embedded tissues using multiplex polymerase chain reaction-based assay. Arch. Pathol. Lab. Med., 134:620–624 (2010). Резюме публикации.
  83. R. Janavicius, R. Adomaitis, F. Jankevicius, L. Griskevicius, Extremely low risk of pheochromocytomas in complete VHL gene deletion cases. Hum. Mutat., 30:1365–1366; author reply 7 (2009). Резюме публикации.
  84. L. Griskevicius, R. Stulpinas, I. Vengalyte, S. Saulyte-Trakymiene, U. Mickys, D. Pranys, J. Kurtinaitis, M. Jurgutis, Favorable outcome with chemo-immunotherapy in Burkitt lymphoma and leukemia. Leuk. Res., 33:587–588 (2009). Резюме публикации.
  85. E. Gineikiene, M. Stoskus, L. Griskevicius, Single nucleotide polymorphism-based system improves the applicability of quantitative PCR for chimerism monitoring. J. Mol. Diagn., 11:66–74 (2009). Резюме публикации.
  86. Janavicius R, Pepalyte I, Kucinskas V. Novel and common BRCA1 mutations in familial breast/ovarian cancer patients from Lithuania. Breast Cancer Res Treat. Sep; 117(2):467-9. (2009).
  87. E. Gineikiene, M. Stoskus, L. Griskevicius, Recent advances in quantitative chimerism analysis. Expert Rev. Mol. Diagn., 9:817–832 (2009). Резюме публикации.
  88. Engert, L. Griskevicius, Y. Zyuzgin, H. Lubenau, A. del Giglio, XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy. Leuk. Lymphoma, 50:374–379 (2009). Резюме публикации.
  89. M. Balciunas, L. Bagdonaite, R. Samalavicius, L. Griskevicius, A. Vuylsteke, Pre-operative high sensitive C-reactive protein predicts cardiovascular events after coronary artery bypass grafting surgery: a prospective observational study. Ann. Card. Anaesth., 12:127–132 (2009). Резюме публикации.
  90. M. Balciunas, L. Bagdonaite, R. Samalavicius, L. Griskevicius, Evaluation of the impact of coronary artery bypass grafting surgery on soluble markers of endothelial activation, vascular and intercellular adhesion molecules. Seminars in Cardiovascular medicine, 15(1):4 (2009).
  91. J. Korsakas, K. Andrekute-Aleksiejiene, A. Bukauskas, B. Brasiuniene, F. Jankevicius, L. Griskevicius, Sequential high-dose chemotherapy with hematopoietic stem-cell support in poor risk, relapsed or refractory germ-cell tumor patient treatment: Lithuanian experience. European Urology Supplements, 8(8):600-601 (2009).
  92. Jakubauskas A, Kriukiene E, Trinkunaite L, Sapranauskas R, Jurenaite-Urbanaviciene S, Lubys A. Bioinformatic and partial functional analysis of pEspA and pEspB, two plasmids from Exiguobacterium arabatum sp. nov. RFL1109. Plasmid, 61:52-64 (2009). Резюме публикации.
  93. N.R. Valevičienė, E. Sadauskienė, Z. Petrulionienė, M. Matačiūnas, D. Zakaraitė, A. Tamošiūnas, L. Griškevičius, S. Glaveckaitė, A. Laucevičius, Diagnosis, treatment and subsequent remission of a rare tumor – primary cardiac lymphoma. Seminars in Cardiovascular Medicine, 14(5):1-6 (2008).
  94. R. Kviliute, A. Paskevicius, J. Gulbinovic, R. Stulpinas, L. Griskevicius, Nonfatal Trichoderma citrinoviride pneumonia in an acute myeloid leukemia patient. Ann. Hematol., 87:501–502 (2008).
  95. Jakubauskas A, Sasnauskas G, Giedriene J, Janulaitis A. Domain organization and functional analysis of Type IIS restriction endonuclease Eco31I. Biochemistry, 47:8546-8556 (2008). Резюме публикации.
  96. M. Balciunas, L. Bagdonaite, A. Baublys, L. Griskevicius L, Impact of perioperative endothelial function on cardiovascular complications after on pump coronary artery bypass grafting surgery. Laboratorine medicina, 9(4):180-185 (2007).
  97. J. Priluckiene, I. Kriukelyte, M. Jurgutis, I. Trociukas, [Chronic graft-versus-host disease presenting as nephrotic syndrome after allogenic hematopoietic stem cell transplantation]. Medicina (Kaunas) 43 Suppl 1:148–152 (2007). Резюме публикации.
  98. U. Dumpis, J. Gulbinovic, J. Struwe, A. Lagergren, L. Griskevicius, U. Bergman, Differences in antibiotic prescribing in three university hospitals in the Baltic region revealed by a simple protocol for quality assessment of therapeutic indications. Int. J. Clin. Pharmacol. Ther., 45:568–576 (2007). Резюме публикации.
  99. Jakubauskas A, Giedriene J, Bujnicki JM, Janulaitis A. Identification of a single HNH active site in Type IIS restriction endonuclease Eco31I. Journal of Molecular Biology, 370:157-169 (2007). Резюме публикации.
  100. H. Xie, L. Griskevicius, L. Stahle, Z. Hassan, U. Yasar, A. Rane, U. Broberg, E. Kimby, M. Hassan, Pharmacogenetics of cyclophosphamide in patients with hematological malignancies. Eur. J. Pharm. Sci., 27:54–61 (2006). Резюме публикации.
  101. F. Sjoo, Z. Hassan, M. Abedi-Valugerdi, L. Griskevicius, C. Nilsson, M. Remberger, J. Aschan, H. Concha, U. Gaughan, M. Hassan, Myeloablative and immunosuppressive properties of treosulfan in mice. Exp. Hematol., 34:115–121 (2006). Резюме публикации.
  102. Tamulaitiene G, Jakubauskas A, Urbanke C, Huber R, Grazulis S, Siksnys V. The crystal structure of the rare-cutting restriction enzyme SdaI reveals unexpected domain architecture. Structure, 14: 1389-1400 (2006). Резюме публикации.
  103. Azarinskas A, Maneliene Z, Jakubauskas A. Hin4II, a novel prototype restriction endonuclease from Haemophilus influenzae RFL4: discovery, cloning and expression in Escherichia coli. Journal of Biotechnology, 123: 288-296 (2006). Резюме публикации.
  104. Eidukevicius R, Characiejus D, Janavicius R, Kazlauskaite N, Pasukoniene V, Mauricas M, Den Otter W.: A method to estimate cell cycle time and growth fraction using bromodeoxyuridine-flow cytometry data from a single sample. BMC Cancer. Sep 22; 5:122 (2005). Резюме публикации.
  105. Tiemann B, Depping R, Gineikiene E, Kaliniene L, Nivinskas R, Rüger W. ModA and ModB, two ADP-ribosyltransferases encoded by bacteriophage T4: catalytic properties and mutation analysis. J Bacteriol. 2004 Nov; 186(21):7262-72. Publikacijos santrauka.
  106. H.J. Xie, U. Yasar, S. Lundgren, L. Griskevicius, Y. Terelius, M. Hassan, A. Rane, Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics J., 3:53–61 (2003). Резюме публикации.
  107. H.J. Xie, U. Broberg, L. Griskevicius, S. Lundgren, S. Carlens, L. Meurling, C. Paul, A. Rane, M. Hassan, Alteration of pharmacokinetics of cyclophosphamide and suppression of the cytochrome p450 genes by ciprofloxacin. Bone Marrow Transplant., 31:197–203 (2003). Резюме публикации.
  108. L. Griskevicius, U. Yasar, M. Sandberg, M. Hidestrand, E. Eliasson, G. Tybring, M. Hassan, M.L. Dahl, Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes. Eur. J. Clin. Pharmacol., 59:103–109 (2003). Резюме публикации.
  109. L. Griskevicius, L. Meurling, M. Hassan, Simple method based on fluorescent detection for the determination of 4-hydroxycyclophosphamide in plasma. Ther. Drug Monit., 24:405–409 (2002). Резюме публикации.
  110. Bitinaite J, Mitkaite G, Dauksaite V, Jakubauskas A, Timinskas A, Vaisvila R, Lubys A, Janulaitis A. Evolutionary relationship of Alw26I, Eco31I and Esp3I, restriction endonucleases that recognise overlapping sequences. Molecular Genetics and Genomics, 267:664-672 (2002). Резюме публикации.
  111. L. Griskevicius, J. Gulbinovic, I. Trociukas, et al., Neprognozuojama ciclofosfomido ir 4-hidroksiciclofosfomido farmokokinetika vartojant įprastinę ciclofosfomido dozę. Laboratorinė medicina, 4:21-28 (2001).
  112. Sommer N, Salniene V, Gineikiene E, Nivinskas R, Rüger W. T4 early promoter strength probed in vivo with unribosylated and ADP-ribosylated Escherichia coli RNA polymerase: a mutation analysis. Microbiology. 2000 Oct; 146(Pt 10):2643-53. Резюме публикации.
  113. J. Dadonienė, I. Trociukas, V. Gražienė, Z. Mackevičius, Idiopathic Hypereosinophilic Syndrome on the Border with Churg-Sraus Vasculitis. ISSN 1292-0138. Acta medicina Lithuanica, 6(2):135-137 (1999).
  114. Nivinskas R, Malys N, Klausa V, Vaiskunaite R, Gineikiene E. Post-transcriptional control of bacteriophage T4 gene 25 expression: mRNA secondary structure that enhances translational initiation. J Mol Biol. 1999 May 7; 288(3):291-304. Резюме публикации.
  115. Gircontaitė, M. Leckienė, I. Trociuk, V. Giedraitis, M. Mauricas, A rapid ELISA test for detection of human paraproteins. Eur J Clin Chem Clin Biochem, 34:349-353 (1996). Резюме публикации.
  116. J. Balsys, V.A. Bumelis, I. Gircontaitė, M. Leckienė, M. Mauricas, I. Trociuk, Total and monoclonal immunoglobulin detection and qantification in human sera by enzyme-liked immunosorbent assay., ISSN 1392 – 0146. Biology, N3, 65 – 72 (1994).

Доклады, прочитанные на международных конференциях:

  1. Bukauskas A., Stoskus M., Valceckiene V., Rucinskaite G., Mickeviciute O., Slobinas A., Jucaitiene R., Slepikiene I, Peceliunas V., Trociukas I., Griskevicius L., Mesenchymal stromal cells in patients with steroid-refractory III-IV grade acute graft versus host disease after allogeneic hematopoietic stem cell transplantation or donor lymphocyte infusion. EBMT Conference, Lisbon, Portugal (2018)
  2. Bukauskas A., Stoskus M., Valceckiene V., Griskevicius L., Small scale production of clinical grade MSCS for a single center setting. EBMT Conference, Lisbon, Portugal (2018)
  3. Rucinskaite G., Cekauskiene R., Mickeviciute O., Trociukas I., Griskevicius L., Peceliunas V. EBMT risk score impact on mortality rate for allogeneic hematopoietic stem cell transplantation.EBMT Conference, Lisbon, Portugal (2018)
  4. Jakubauskas A., Cekauskiene R. Griskevicius L. Impact of anti-HLA antibodies on early complications and outcome after unrelated donor haematopoietics stem cell transplantation (HSCT). EBMT Conference, Lisbon, Portugal (2018)
  5. Cekauskiene R., Maciutaite E., Lizaitis M., Simutiene L., Trociukas I., Griskevicius L. CMV seropositive donor selection for CMV seropositive stem cell transplant recipients reduces CMV reactivation frequency and duration. EBMT Conference,  Marseille, France (2017).
  6. Rucinskaite G., Cekauskiene R., Mickeviciute O., Trociukas I., Griskevicius L., Peceliunas V. Hematopoetic stem cell transplantation Comorbidity Index in transplant recipients and impact of pulmonary and cardiac function values on it’s score. EBMT Conference,  Marseille, France (2017).
  7. Vicent Claramunta A., Paskevicius A. , Svediene J. , Gudeliunaite E., Kiveryte S., Petrauskaite R., Griskevicius L., Zolumskis A., Naujalis E. Thermal Desorption Methodology for Volatile Organic Compounds (VOCs) Identification: Possible Application in Invasive Fungal Infections. Summer school for Metrology: Metrology for Quality of Life. Italy (2016).
  8. Bukauskas A, Valceckiene V., Stoskus M, Jureviciute V, Bertasiute R, Peceliunas V., Slobinas A., Trociukas I., Griskevičius L. Mesenchymal stromal cells in patients with steroid-refractory III-IV grade Acute Graft versus Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation or Donor Lymphocyte Infusion. EBMT Conference, Valencia (2016)
  9. Valceckiene V., Stoskus M., Bukauskas A, Griskevicius L. Towards a more economical large-scale production of clinical grade MSCs. EBMT Conference, Valencia (2016)
  10. Cekauskiene R., B. Valatkaite B., Griskevicius L., Jakubauskas A. Relevance of anti-HLA antibodies in unrelated donor allogeneic haematopoietic stem cell transplantation. Bone Marrow Transpl 2016; EBMT Conference, Valencia (2016)
  11. R. Cekauskiene. Extracorporeal photopheresis in GvHD treatment, Vilnius University BMT dpt. Experience. 9th Baltic Conference of hematology, April 24-26, Vilnius (2014)
  12. R. Cekauskiene. Lithuanian Bone Marrow Donor Registry - 10 years of experience. 9th Baltic Conference of hematology, April 24-26, Vilnius (2014)
  13. A Beiša, V Beiša, E Ostanevičiūtė, M Stoškus, D Juškevičius, D Petroška, L Griškevičius, K Strupas, BRAF V600E-opportunity to decrease the amount of thyroid surgery. Langenbeck‘s Archive of Surgery. 5th ESES Workshop-Surgery of Thyroid Cancer, vol. 398, p. 759-788 (2013).
  14. V. Peceliunas, BM and PB plasma cell subpopulation analysis by multicolor flow cytometry. Nordic Stem Cell treatment, Scientific Meeting. November 26th, Oslo (2012).
  15. L. Kryzauskaite, L. Deberdt, L. Rouse, R. Goodrich, Mirasol® PRT Treated Platelet Products in Autologous Stem Cell Transplant Patients. Transfusion, 51, Suppl. s3, pp. 37A–38A (2011).
  16. R. Pileckyte, High Dose Methylprednisolone (HDMP) and Rituximab (RTX) are Effective in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) with High Genetic Risk. Abstract book of 7th Baltic Conference of Hematology, may 20-22, p. 19 (2010)
  17. M. Stoskus, Expression Analysis of IMP Family Isoforms in Acute and Chronic Leukemia Reveals a Unique Profile of ETV6/RUNX1 Entity and Highlights Potential IMO Profiling Utility in Other B Lineage Neoplasms. Abstract book of 7th Baltic Conference of Hematology, may 20-22, p. 20 (2010)

Доклады, опубликованные в сборниках, составленных по материалам международных конференций:

  1. Dapkeviciute A., Griskevicius L., Sapoka V., Martynova E., Peceliunas V.  Time from symptom onset to diagnosis and treatment among hematological malignancies: disease, patient and health system related influencing factors. Abstract book of 23nd Congress of the European Hematology Association, Stockholm, Sweden, June 14-17 (2018).
  2. Utke Rank C.,  …, Griskevicius L., et al., Thromboembolism in ALL Patients 1-45 Years Treated According to the NOPHO-ALL 2008 Protocol.  Abstract book of  59th ASH annual meeting, Atlanta, December 9-12 (2017)
  3. Dirse V., Drachneris J., Mickys U., Stoskus M., Griskevicius L. Genomic prifiling of BCL2 and MYC double expressior diffuse large B cell lymphoma.  Abstract book of 22nd Congress of the European Hematology Association, Madrid, June 22-25 (2017).
  4.  Norvilas R., Dirse V., Gineikiene E., Mickeviciute O., Pakstyte S., Stoskus M., Griskevicius L. Association analysis of cytogenetic and genetic and genetic alterations in primary myelofibrosis. Abstract book of 22nd Congress of the European Hematology Association, Madrid, June 22-25 (2017).
  5.  Beisa A, Kvietkauskas M, Beisa V, Stoskus M, Ostaneviciute E, Griskevičius L, Strupas K. The utility of the Bethesda category and its association with BRAF mutation in the prediction of papillary thyroid cancer stage. Poster presentation at 7th Symposium of European society of endocrine surgery (ESES). Oxford, UK (2017). 
  6. Pileckyte R., Klimiene I., Valceckiene V., Sejoniene J., Viselgaite L., Zvirblis T., Griskevicius L. Rituximab in addition to methylprednisolone in pretreated elderly or unfit patients with B chronic lymphocytic leukemia. Poster Presentation at the XVI International Workshop on Chronic Lymphocytic Leukaemia, September 7-9, Sydney (2015)
  7. Brand, B., ..., Griskevicius, L. et al. Perioperative Efficacy of an Extended Half-Life, Pegylated, Full-Length, Recombinant Factor VIII (BAX 855) in Individual Procedures. Abstract of 57th ASH Annual Meeting and Exposition, December 5-8, Orlando, Florida (2015).
  8. Atkinson, V., ..., Tulyte, S. et al. Safety and Effectiveness Analysis of V600 BRAF-Mutated Metastatic Melanoma Patients From the Dabrafenib Plus Trametinib Named Patient Program – DESCRIBE II Study. Poster Presentation at the 18th ECC – 40th ESMO European Cancer Congress, Vienna, Austria, 25-29 September (2015).
  9. Brand, B., ..., Griskevicius, L. et al. Initial results of a clinical trial evaluating a full-lenght pegylated recombinant factor VIII with extended half-life for the perioperative control of hemostasis in hemophilia A. Abstract of Congress of the International Society on Thrombosis and Hemostasis, Toronto, June 20-25, (2015).
  10. Ivaskevicius, V., Goldmann, G., Kryzauskaite, L., Rutkauskiene, G., Horneff, S., Marquardt, N., Pavlova, A., Oldenburg, J. Congenital FXI Deficiency: A Report of Nine Families From Germany And Lithuania. Abstract of Congress of the International Society on Thrombosis and Hemostasis, Toronto, June 20-25, (2015).
  11. Hellman, A., ..., Griskevicius, L. et al. : Efficacy and Safety of Frontline Nilotinib in 1089 European Patients With CML-CP: ENEST1st Final Analysis. Abstract of European Hematology Association 20th Congress, Vienna, June 11-14, (2015).
  12. Beisa, L., ..., Griskevicius, L. et al. The potential utility of BRAF V600E status follow-up in FNA of thyroid nodules. Hyperparathyroidism due multiple glanda disease: an evidence-based perspective, Varna, Bulgaria, May 28-30, (2015).
  13. Cekauskiene, R., Extracorporeal Photopheresis and Rituximab for the Treatment of Steroid Refractory Graft versus Host Disease. EBMT Conference, Milan (2014)
  14. M Stoskus, A Eidukaite, L Griskevicius, ETV6/RUNX1 transcript is a potential target of RNA-binding protein IGF2BP1. Abstract book of 18th Congress of the European Hematology Association, Stockholm, June 13-16, p. 6 (2013).
  15. V Dirse, T Zvirblis, L Griskevicius, SNP array analysis of adult ALL: a population based study of lithuanian patients. Abstract book of 18th Congress of the European Hematology Association, Stockholm, June 13-16, p. 7 (2013).
  16. R Pileckyte, T Zvirblis, V Ivanauskaite, I Klimiene, L Griskevicius, Chronic lymphocytic leukemia (CLL): epidemiology, comorbidities and treatment preference in daily clinical practice. Abstract book of 18th Congress of the European Hematology Association, Stockholm, June 13-16, p. 546 (2013).
  17. V Peceliunas, A Bertasiute, T Zvirblis, L Griskevicius, Second autologous transplantation for patients with relapsed multiple myeloma. Abstract book of 18th Congress of the European Hematology Association, Stockholm, June 13-16, p. 608 (2013).
  18. R Stulpinas, J Drachneris, A Simbelyte, L Griskevicius, U Mickys, Fulicullar lymphoma in situ: serious of 8 cases. Abstract book of 18th Congress of the European Hematology Association, Stockholm, June 13-16, p. 647 (2013).
  19. R. Cekauskiene. Mononuclear cell collection for Extracorporeal photopheresis in Graft versus host disease patients: a comparison of Cobe Spectra and Spectra Optia devices. EBMT Conference, July 7-10, London (2013)
  20. G. Barosi, M. B. Agarwal, S. Zweegman, W. Willenbacher, S. Pakstyte, R. Raymakers, N. Cantoni, A. Modi, M. Khan, J. R. Perez, H. Hasselbalch, J. P. V. Viveros, C. Linardi, H.Gisslinger, A. H. D. Gabriel, F. Palandri, D. Lavie, C. Harrison: An individual patient supply program for ruxolitinib for the treatment of patiens with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis. 54th ASH Annual Meeting and Exposition, December 8-11, Atlanta, Georgia (2012).
  21. A Hochhaus, G Rosti, P Le Coutre, G Ossenkoppele, L Griskevicius, D Réa, A Hellmann, T Masszi, J Steegmann, FX Mahon, K Porkka, N Cross, M Müller, C Piccolo, P Schuld, A Pellegrino, F Giles, ENEST1ST: Nilotinib in patients with newly diagnosed chrnic myeloid leukemia in chronic phase (CML-CP): a Eauropean and EUTOS clinical initiative for standardization of molecular response. Abstract book of 17th Congress of the European Hematology Association, Amsterdam, June 14-17, p. 74 (2012).
  22. T Zvirblis, V Ivanauskaite, I Tavoriene, R Gerbutavicius, E Juozaityte, L Malciute, M Jurgutis, J Daubariene, D Ramanauskiene, L Rageliene, L Griskevicius, Increasing relative survival in chronic myeloid leukemija (CML): a population-based study in Lithuania. Abstract book of 17th Congress of the European Hematology Association, Amsterdam, June 14-17, p. 312-313 (2012).
  23. R Pileckyte, V Valceckiene, T Zvirblis, L Griskevicius, Dose dense high dose methylprednisolone (HDMP) and rituximab (RTX) are effective in relapsed chronic lymphocytic leukemia (CLL) with 17p deletion (17p del)/TP53 mutation. Abstract book of 17th Congress of the European Hematology Association, Amsterdam, June 525-526, p. 74 (2012).
  24. Miglinas, Marius, Ašakienė, Eglė, Vareikienė, Loreta, Aleknienė, Dalia, Supranavičienė, Lilija, Rimševičius, Laurynas, Želvys, Arūnas, Griškevičius, Antanas, Griškevičius, Laimonas, The first AB0-incompatible kidney transplantation in Lithuania and Baltic States. Abstract book of 10th Baltic Nephrology Conference, Tartu, September 20-22, p. 55 (2012).
  25. Janavičius, Ramūnas, Rudaitis, Vilius, Griškevičius, Laimonas, Comprehensive BRCA1 and BRCA2 mutational profile in Lithuania. European journal of human genetics : European human genetics conference, Nurnberg, June 23-26, p. 161 (2012).
  26. Daunoravičius, Dainius, Jakubauskas, Artūras, Griškevičius, Laimonas, Čibiras, Sigitas Vladas, Žurauskas, Edvardas, Maneikienė, Vytė Valerija, Čelutkienė, Jelena, Ručinskas, Kęstutis, Jasulaitis, Algimantas, Grabauskienė, Virginija, Inflammatory cardiomyopathy: aetiopathogenetic markers for diagnosis of disease subentities and for aetiology directed treatment. Abstract book of Heart Failure Congress, Belgrade, May 19-22 (2012).
  27. D. Palionis, A. Tamosiunas, J. Rascon, L. Rageliene, S. Stankeviciene, T. Zvirblis, Assessment of Trsnfusion Related Cardiac and Liver Iron Overload in Child Patients with MRI T2* Technique: Single Center Initial Experience, ELN Frontier Meeting 2012, Istanbul, Turkey, November 9-11, p. 33 (2012).
  28. R. Cekauskiene. Lithuanian Bone Marrow Donor Registry: experience of 2004-2011. Practical Aspects of Donor-Recipient Matching, HSCT Conference, December 17-18, Wroclaw (2012)
  29. R. Cekauskiene, L. Kryzauskaite, A. Griskevicius, K. Sinkevic, R. Matuzeviciene, T. Zvirblis, I. Trociukas, L. Griskevicius, Extracorporeal photopheresis (ECP) and rituximab (RTX) for the treatment of steroid refractory graft versus host disease (SR-GVHD). Abstract book of 16th Congress of the European Hematology Association, London, June 9–12, p. 179 (2011).
  30. V. Peceliunas, A. Janiulioniene, R. Matuzeviciene, T. Zvirblis, L. Griskevicius, Circulating plasma cells (CPCS) predict the outcome of relapsed or refractory multiple myeloma (RR MM). Abstract book of 16th Congress of the European Hematology Association, London, June 9–12, p. 369–370 (2011).
  31. T. Zvirblis, I. Vengalyte, R. Pileckyte, D. Pranys, M. Jurgutis, L. Griskevicius, Population based analysis of chemo-immunotherapy in adult Burkitt lymphoma and leukaemia (BLL). Abstract book of 16th Congress of the European Hematology Association, London, June 9–12, p. 399–400 (2011).
  32. J. Hasford, A. Almeida, M. Baccarani, A. Bogdanovic, R. Clark, A. Colita, P. Costeas, E. Demeckova, I. Dyagil, H. Everaus, L. Griskevicius, J. Guilhot, R. Hehlmann, A. Hellmann, V. Hoffmann, K. Indrak, P. Koskenvesa, B. Labar, S. Lejniece, D. Lindoerfer, G. Ossenkoppele, P. Panagiotidis, G. Rosti, B. Simonsson, J. Steegmann, J. Thaler, A. Turkina, D. Zackova, A. Zaritskey, I. Zupan, The European Population-based CML Registry Objectives and First Results. Abstract book of 16th Congress of the European Hematology Association, London, June 9–12, p. 399–400 (2011).
  33. R. Pileckyte, R. Matuzeviciene, A. Janiulioniene, M. Jurgutis, T. Zvirblis, L Griskevicius, T regulatory cells (TREG) in relapsed/refractory chronic lymphocytic leukemia (CLL) treated with high dose methylprednisolone (HDMP) and rituximab. Abstract book of 16th Congress of the European Hematology Association, London, June 9–12, p. 279 (2011).
  34. M. Stoskus, E. Gineikiene, V. Valceckiene, B. Valatkaite, R. Pileckyte, L. Griskevicius, Identification of characteristic IGF2BP expression patterns in B-lineage neoplasms. Abstract book of 16th Congress of the European Hematology Association, London, June 9–12, p. 311 (2011).
  35. A. Macioniene, S. Kiveryte, Z. Kucinskiene, J. Gulbinovic, L. Griskevicius, A. Jakubauskas. Real-time PCR typing of CTX-M and SHV family genes of extended-spectrum beta-lactamase-producing Enterobacteriaceae clinical isolates from Vilnius University Hospital Santariskiu Clinics, Lithuania. 21st ECCMID – 27th ICC, Milan (2011).
  36. R.Cekauskiene. Combined Extracorporeal Photopheresis (ECP) and Rituximab (Rtx) for the Treatment of Steroid Refractory Graft versus Host Disease (SR-GvHD) after Allogeneic Stem Cell Transplantation (alloSCT). ISFA Conference, September 14-17, Vienna (2011)
  37. E. Gineikiene, M. Stoskus, L. Griskevicius, SNP-based system improves the applicability of qPCR for chimerism monitoring. Eur. J. Human Genetics: European Human Genetic Conference 2009, May. 17, Suppl. 2, p. 285 (2009).
  38. R. Cekauskiene, Lithuanian National Bone Marrow Donor Registry (LBMDR) – 6 years of experience. Abstract book of 7th Baltic Conference of Hematology, may 20-22, p. 35 (2010).
  39. A. Degulys, R. Pileckyte, E. Gineikiene, V. Valceckiene, M. Stoskus, R. Dambrauskiene, U. Mickys, L. Griskevicius, Bilineage involvement of the fusion gene in a patient with FIP1L1-PDGFRA positive chronic eosinophilic leukemia and T-cell lymphoblastic lymphoma: a case report. Abstract book of 7th Baltic Conference of Hematology, may 20-22, p. 37 (2010).
  40. A. Degulys, R. Pileckyte, E. Gineikiene, V. Valceckiene, M. Stoskus, R. Dambrauskiene, U. Mickys, L. Griskevicius, Bilineage involvement of the fusion gene in a patient with FIP1L1-PDGFRA positive chronic eosinophilic leukemia and T-cell lymphoblastic lymphoma: a case report. Abstract book of 15th Congress of the European Hematology Association, Barcelona, June 10–13, p. 601 (2010).
  41. R. Pileckyte, N. Gailiute, L. Malciute, A. Drungiene, L. Griskevicius, Repeated administration of low dose monoclonal antiCD20 antibody rituximab (Rtx) in refractory acquired hemophilia A (AHA): a case report.
  42. R. Pileckyte, I. Vengalyte, L. Griskevicius, Rare infections in primary Hodgkin‘s disease.
  43. I. Vengalyte, R. Pileckyte, L. Griskevicius, Aspergillus Galactomannan antigen in the bronchoalveolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis in hematological patients. Abstract book of 15th Congress of the European Hematology Association, Barcelona, June 10–13, p. 364 (2010).
  44. V. Peceliunas, A. Janiulioniene, R. Matuzeviciene, L. Griskevicius, Circulating plasma cells (CPC) predict the outcome of relapsed or refractory multiple myeloma (RR MM). Abstract book of 15th Congress of the European Hematology Association, Barcelona, June 10–13, p. 396 (2010).
  45. R. Pileckyte, M. Jurgutis, V. Valceckiene, M. Stoskus, E. Gineikiene, J. Sejoniene, A. Degulys, A. Jakubauskas, L. Griskevicius, Dose dense high dose methylprednisolone (HDMP) and rituximab (RTX) are effective in relapsed or refractory high risk chronic lymphocytic leukemia (CLL). Abstract book of 15th Congress of the European Hematology Association, Barcelona, June 10–13, p. 325 (2010).
  46. A. Petzer, D. Wolf, D. Fong, T. Lion, I. Dyagil, Z. Masliak, A. Bogdanovic, L. Griskevicius, S. Lejniece, S. Goranov, L. Gercheva, A. Stojanovic, D. Peytchev, N. Tzvetkov, R. Griniute, R. Oucheva, T. Grubinger, M. Kwakkelstein, F. Rancati, G. Gastl, High dose imatinib induction (800 mg/day, 6 months) induces significantly higher cytogenetic and molecular responses in pre-treated chronic phase CML – Phase III CELSG 'ISTAHIT' trial – First results. Abstract book of 15th Congress of the European Hematology Association, Barcelona, June 10–13, p. 53 (2010).
  47. G. Wierda, T. Kipps, J. Dürig, L. Griskevicius, S. Stilgenbauer, J. Mayer, L. Smolej, G. Hess, R. Griniute, F. Hernandez-Ilizaliturri, S. Padmanabhan, M. Gorczyca, I. Gupta, T. Nielsen, C. Russell, Chemoimmunotherapy with ofatumumab, fludarabine and cyclophosphamide in previously untreated patients with chronic lymphocytic leukemia: A phase II international trial. Abstract book of 15th Congress of the European Hematology Association, Barcelona, June 10–13, pp. 320–321 (2010).
  48. A. Bukauskas, J. Korskas, K. Andrekute-Aleksiejiene, B. Brasiuniene, I. Trociukas, F. Jankevicius, L. Griskevicius, Sequential high-dose chemotherapy with hematopoietic stem-cell tumor patient treatment: Lithuanian experience. EAU 3rd Norh Eastern European Meeting (NEEM), September 11-12, p. 92 (2009).
  49. L. Griskevicius, A. Slobinas, I. Trociukas, J. Balsys, Early experience with high dose Cytarabine (HD AraC) in the treatment of Acute Leukemia at Vilnius University Hospital Santariskiu Klinikos. Second Baltic States Haematologists Congress, Riga, June 7-9, p. 19 (2000).
Atnaujinta 2019-02-04
Straipsnis parodytas: 17444 kartų(kartus)
 
Reklaminis skydelis
Reklaminis skydelis
Reklaminis skydelis
Reklaminis skydelis

Siekdami pagerinti Jūsų naršymo patirtį lankantis Santa.lt svetainėje, naudojame slapukus (angl. cookies) – tai nedidelės informacijos rinkmenos, kurias jūsų naudojamo įrenginio naršyklė priima iš svetainės kurioje lankotės. Surinkta informacija iš slapukų mums padeda efektyviau nustatyti naršymo įpročius, veiksmus bei nustatymus (pvz., kalbą, šrifto dydį ir kitas rodymo parinktis), o jums nereikia jų kaskart pasirinkti lankantis svetainėje ar naršant įvairiuose jos puslapiuose. Kad interneto svetainė veiktų, nebūtina leisti naudoti šiuos slapukus, bet sutikus su slapukų politika, naršyti jums bus paprasčiau. Išsamesnė informacija suteikiama AllAboutCookies.org. Galite ištrinti visus jau esančius jūsų kompiuteryje slapukus, o dauguma naršyklių nustatytos taip, kad slapukai nebūtų įrašomi jūsų įrenginyje. Su slapukais susijusi informacija nenaudojama jūsų tapatybei nustatyti ar kitais nei pirmiau aprašytais tikslais. Daugiau apie slapukus ir kaip jų atsisakyti - privatumo politikoje.

EU Cookie Directive plugin by www.channeldigital.co.uk